Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting

Rhea-AI Summary

Tivic (Nasdaq:TIVC) presented Entolimod at a TechWatch meeting with BARDA and U.S. defense and health agencies on January 26, 2026. The company showcased clinical results and manufacturing readiness accelerated by new subsidiary Velocity Bioworks, and BARDA requested an expedited follow-up to continue discussions about potential inclusion in the Strategic National Stockpile.

The meeting started formal engagement with BARDA, DoD, DTRA, NIH and NIAID to evaluate Entolimod as a therapeutic and prophylactic radiation medical countermeasure.

Positive

• BARDA requested an expedited follow-up meeting
• Clinical results and manufacturing readiness were showcased
• Velocity Bioworks accelerating manufacturing preparedness

Negative

• No binding procurement or funding commitment from BARDA yet
• Regulatory acceptance and stockpile inclusion remain unconfirmed

News Market Reaction

-1.56%

4 alerts

-1.56% News Effect

-13.9% Trough Tracked

-$51K Valuation Impact

$3M Market Cap

1.4x Rel. Volume

On the day this news was published, TIVC declined 1.56%, reflecting a mild negative market reaction. Argus tracked a trough of -13.9% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $51K from the company's valuation, bringing the market cap to $3M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

TechWatch meeting date: January 26, 2026

1 metrics

TechWatch meeting date January 26, 2026 Date of BARDA TechWatch presentation on Entolimod

Market Reality Check

Price: $1.19 Vol: Volume 79,149 is below th...

low vol

$1.19 Last Close

Volume Volume 79,149 is below the 129,665 20-day average (relative volume 0.61x). low

Technical Shares at $1.28 are trading below the 200-day MA of $3.14 and 91.82% under the 52-week high.

Peers on Argus

TIVC was up 7.11% while key peers showed mixed action; scanner-flagged peers NUW...

2 Down

TIVC was up 7.11% while key peers showed mixed action; scanner-flagged peers NUWE and MOVE were both down (median about -8.9%), indicating the move was more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Jan 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 26	Conference presentation	Positive	-4.4%	Outlined strategic pivot and commercialization path for Entolimod at DealFlow conference.
Jan 20	Investor conference	Positive	+0.8%	CEO corporate update on Entolimod milestones and Velocity Bioworks integration.
Jan 12	Manufacturing update	Positive	+2.2%	Reported 200x Entolimod manufacturing scale-up with validated 50-liter batch data.
Jan 08	Acquisition webcast	Positive	+6.0%	Announced webcast on CDMO asset acquisition and impact on Entolimod timelines.
Dec 11	CDMO acquisition	Positive	+11.8%	Acquired cGMP assets and launched Velocity Bioworks with a $90M+ financing package.

Pattern Detected

Recent news has generally been positive and the stock has more often reacted in the same direction, with one notable divergence on conference-related news.

Recent Company History

Over the past several months, Tivic has focused on advancing Entolimod and in‑house manufacturing. The company acquired CDMO assets and launched Velocity Bioworks, supported by a financing package exceeding $90M. Subsequent updates highlighted a 200x manufacturing scale-up, cell line verification, and progress toward cGMP and a potential BLA for ARS. Multiple conference presentations outlined this strategic pivot. Today’s BARDA TechWatch follow-up fits into this sequence of Entolimod-focused development and commercialization steps.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-17

Tivic has an effective S-3 resale shelf dated Oct 17, 2025, covering up to 1,580,437 registered shares for selling stockholders. The company does not receive proceeds from resales except upon potential warrant exercises. The shelf has been used in at least 4 prospectus supplements, indicating ongoing resale capacity.

Market Pulse Summary

This announcement highlights BARDA’s continued engagement with Tivic’s TLR5 agonist Entolimod for ac...

Analysis

This announcement highlights BARDA’s continued engagement with Tivic’s TLR5 agonist Entolimod for acute radiation syndrome, including discussions about potential inclusion in the Strategic National Stockpile. It builds on recent updates around Velocity Bioworks, manufacturing scale-up, and a broader strategic pivot toward biologics. Investors may focus on future BARDA follow-ups, concrete funding or procurement decisions, and any changes to financing structures or registered share overhang, including the active S-3 resale registration covering 1,580,437 shares.

Key Terms

acute radiation syndrome, ionizing radiation, gastrointestinal, hematopoietic, +4 more

8 terms

acute radiation syndrome medical

"for treating ARS"

Acute radiation syndrome is the sudden illness that happens after a person absorbs a large dose of ionizing radiation in a short time, damaging blood cells, the gut, skin, and other organs. Think of it like a severe, internal burn that can impair a person’s ability to heal and fight infection. Investors watch it because outbreaks, accidents, or tests can trigger urgent regulatory action, reshape demand for medical treatments and protective equipment, create liability risks, and affect the operations and stock prices of companies in healthcare, energy, insurance, and related supply chains.

ionizing radiation medical

"from ionizing radiation exposure"

High-energy particles or waves (such as X-rays, gamma rays, or certain fast-moving particles) that can remove electrons from atoms and change chemical structures; imagine tiny, invisible billiard balls or flashes that can knock pieces out of place at the atomic level. Investors care because exposure or use of ionizing radiation drives strict safety rules, permits, cleanup costs, product approvals and liability risks for companies in healthcare, energy, manufacturing and environmental services.

gastrointestinal medical

"mitigate and prevent both gastrointestinal and hematopoietic injury"

Gastrointestinal describes the stomach and intestines and the processes that break down food and absorb nutrients — think of it as the body’s food‑processing and waste‑handling system. For investors, gastrointestinal matters because drugs, devices, or illnesses that affect this system can drive clinical trial outcomes, regulatory decisions, treatment demand and safety concerns, all of which can materially influence revenue, costs and risk for healthcare companies.

hematopoietic medical

"prevent both gastrointestinal and hematopoietic injury"

Hematopoietic describes the biological process and the cells that produce blood—the stem cells in bone marrow that make red blood cells, white blood cells and platelets. It matters to investors because therapies, diagnostics or procedures targeting these cells can drive patient outcomes and market demand; think of hematopoietic function as a factory keeping the body’s delivery and defense systems running, so improvements or failures can affect commercial value and regulatory risk.

toll-like receptor 5 (tlr5) agonist medical

"Tivic's Toll-like Receptor 5 (TLR5) agonist, Entolimod™"

A toll-like receptor 5 (TLR5) agonist is a drug or biologic that activates TLR5, a protein on immune cells that senses a bacterial component and turns on an immune response—like pressing a doorbell to summon the body’s defenders. Investors track these agents because they can enhance vaccines or stimulate immune activity against infections and cancer, offering commercial upside if clinical trials show clear benefit, but they carry safety and regulatory risks common to immune-targeting therapies.

strategic national stockpile regulatory

"incorporating Entolimod into the Strategic National Stockpile"

A strategic national stockpile is a government-held reserve of critical medical supplies, medicines, vaccines and equipment kept to respond quickly to public health emergencies. For investors, it matters because government purchases, replenishment schedules and stockpile policies can create sudden demand, long-term contracts or regulatory priorities that directly affect makers, distributors and suppliers of those goods—think of it as a national emergency pantry that can drive corporate revenue and risk.

radiation countermeasure medical

"its potential use as a radiation countermeasure"

A radiation countermeasure is a drug, vaccine, medical device, or treatment designed to prevent, reduce, or repair harm caused by exposure to ionizing radiation. Think of it as an antidote or protective shield used in accidents or attacks to limit injury and speed recovery. Investors watch these products because they require regulatory approval, can win government procurement or stockpile contracts, and their success or failure can sharply affect a company’s sales and valuation.

prophylactic medical

"as both a therapeutic and prophylactic radiation medical countermeasure"

A prophylactic is a treatment, drug, vaccine, or device used to prevent a disease or medical condition before it occurs, often given to healthy or at‑risk people to reduce the chance of illness. For investors it matters because prophylactics can shrink or stabilize future healthcare costs and change demand patterns—like a seatbelt reducing injury risk, they affect market size, regulatory requirements, pricing power and long‑term revenue predictability.

AI-generated analysis. Not financial advice.

• January 26 Presentation highlighted Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure

• BARDA has requested a follow-up meeting to continue the discussion on the potential utility of Entolimod as a drug for the Strategic National Stockpile

• Showcased clinical results, regulatory progression, and manufacturing readiness accelerated by newly formed subsidiary Velocity Bioworks^™

FREMONT, CA / ACCESS Newswire / January 28, 2026 / Tivic Health^® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that it delivered an invited presentation at a TechWatch meeting with the Biomedical Advanced Research and Development Authority (BARDA) on January 26, 2026, with select members of the Department of Defense (DoD), Defense Threat Reduction Agency (DTRA), National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID). The company presented key clinical and manufacturing readiness data for Tivic's Toll-like Receptor 5 (TLR5) agonist, Entolimod^™, underscoring its potential use as a radiation countermeasure, as well as progress on manufacturing readiness that has been accelerated by newly formed subsidiary Velocity Bioworks.

TechWatch meetings enable BARDA and other U.S. agencies to evaluate technology and manufacturing readiness and to identify potential pathways for funding and purchasing new technologies. Monday's meeting initiated Tivic's discussions with the agency regarding the potential for incorporating Entolimod into the Strategic National Stockpile, with key stakeholders requesting expedited follow-up.

"We appreciate the U.S. government's interest in the differentiated properties of Entolimod compared to the other drugs already stockpiled for treating ARS," said Tivic CEO Jennifer Ernst. "We are fully committed to supporting BARDA and other agencies in their exploration of Entolimod through our upcoming engagements."

"We are pleased that BARDA has recognized Entolimod's potential to provide life-saving benefits to those exposed to lethal doses of ionizing radiation," said Michael K. Handley, COO and President of Biopharma at Tivic. "We look forward to continuing our discussions with BARDA and other federal agencies to advance Entolimod's development as both a therapeutic and prophylactic radiation medical countermeasure."

About BARDA

BARDA is part of the Administration for Strategic Preparedness and Response operating within the U.S. Department of Health and Human Services agency to develop, procure, and stockpile medical countermeasures that address chemical, biologic, radiologic, and nuclear public health threats.

About Entolimod

Entolimod is a novel Toll-like Receptor 5 (TLR5) agonist that triggers NF-kappaB pathway signaling, activating anti-apoptotic and cell protective mechanisms. Entolimod for Acute Radiation Syndrome (ARS) has been the subject of extensive trials under the FDA's Animal Rule and, in animal models, has demonstrated robust survival rates, enhanced gastrointestinal tract recovery, and improved hematopoiesis. To see the complete Tivic pipeline visit: https://tivichealth.com/pipeline/

About Tivic

Tivic is a late-stage immunotherapeutics company whose lead drug candidate, Entolimod™ to treat ARS, is in late-stage development. Entolimod^™ is a TLR5 agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. Tivic's pipeline includes Entolimod^™ to treat Neutropenia, and lymphocyte exhaustion, as well as Entolasta^™, an immunologically optimized variant of Entolimod for chronic applications.

Tivic's wholly owned subsidiary, Velocity Bioworks, is a full-service CDMO based in San Antonio, Texas. Tivic also leverages Velocity Bioworks' manufacturing capabilities to advance its own drug pipeline with the expected benefits of lower costs, accelerated manufacturing outcomes and supply chain security. To learn more about Tivic, visit: https://tivichealth.com/

Forward-Looking Statements

This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim, "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company's interactions with and guidance from the FDA and other regulatory authorities; the continued interest of BARDA and other U.S. government agencies in Entolimod; the ability of the company to achieve the expected benefits from the acquisition of development and manufacturing assets within expected time frames or at all; changes to the company's relationship with its partners; failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of Entolimod, Entolasta or its previously developed bioelectronic platform; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; the company's ability to successfully commercialize its product candidates in the future; changes in the markets and industries in which the company does business; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading "Risk Factors", as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.

Investor Contact:
Hanover International, Inc.
ir@tivichealth.com

Media Contact:
DJ Freyman
DJ@fastrackPR.com

SOURCE: Tivic Health Systems

View the original press release on ACCESS Newswire

FAQ

What did Tivic (TIVC) present to BARDA on January 26, 2026 about Entolimod?

Tivic presented clinical results and manufacturing readiness for Entolimod as a radiation countermeasure. According to the company, the presentation highlighted potential mitigation of gastrointestinal and hematopoietic radiation injury and accelerated manufacturing via Velocity Bioworks.

Did BARDA take action after Tivic's TechWatch presentation on January 26, 2026?

Yes, BARDA requested an expedited follow-up meeting to continue evaluation. According to the company, that follow-up was requested to explore potential pathways for funding and Strategic National Stockpile consideration.

What is Velocity Bioworks' role in Tivic's Entolimod development for TIVC?

Velocity Bioworks is a newly formed subsidiary accelerating manufacturing readiness for Entolimod. According to the company, Velocity Bioworks helped showcase manufacturing preparedness during the TechWatch meeting with BARDA.

Does the TechWatch meeting mean Entolimod will be added to the Strategic National Stockpile for TIVC?

No definitive inclusion decision has been announced following the meeting. According to the company, BARDA requested follow-up discussions but has not committed to procurement or stockpile placement.

Which agencies attended Tivic's TechWatch meeting about Entolimod (TIVC) on January 26, 2026?

Representatives from BARDA, DoD, DTRA, NIH and NIAID participated in the meeting. According to the company, select members from these agencies joined to evaluate technology and manufacturing readiness.